LianBio Eyes ‘Strategic Review’ As It Hands Camzyos Asia Rights Back To MyoKardia Parent BMS

BMS is spending $350m for rights in China and other Asia-Pacific territories for Camzyos • Source: Shutterstock

More from Deals

More from Business